Growth hormone peptides have become one of the most actively researched classes of compounds in modern biomedical science. For Australian researchers and health-conscious individuals, understanding how these peptides work — and which ones show the most promise — is essential for staying at the forefront of peptide science.
Growth hormone secretagogues (GHS) are a family of synthetic peptides that stimulate the pituitary gland to produce and release growth hormone (GH). Unlike exogenous growth hormone administration, these peptides work with your body’s natural feedback mechanisms, promoting a more physiological pattern of GH release. This distinction is critical, as it means the body retains its regulatory control over hormone levels, reducing the risk of supraphysiological spikes that can accompany direct GH injection.
In Australia, peptide research has gained significant momentum over the past decade. Institutions across Sydney, Melbourne, Brisbane, and Perth are actively investigating the therapeutic potential of growth hormone peptides for conditions ranging from age-related muscle wasting to metabolic dysfunction. The Therapeutic Goods Administration (TGA) classifies many of these peptides as research chemicals, making them available for legitimate scientific investigation.
This comprehensive guide explores four of the most promising growth hormone peptides currently available for research in Australia: GHRP-2, GHRP-6, Ipamorelin, and Tesamorelin. We’ll examine the science behind each compound, their mechanisms of action, key research findings, and what makes them unique within the GHS family.
Before diving into individual peptides, it’s worth understanding the fundamental biology that makes growth hormone peptides so fascinating to researchers. Growth hormone is produced by somatotroph cells in the anterior pituitary gland and is regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH) and somatostatin (which inhibits GH release).
Growth hormone secretagogues work primarily through the ghrelin receptor (also known as the growth hormone secretagogue receptor, or GHS-R1a). When these peptides bind to this receptor, they trigger a signalling cascade that results in GH release. Research published in the Journal of Endocrinology has demonstrated that this mechanism is distinct from — and complementary to — the GHRH pathway, meaning GHS peptides can amplify GH release when used alongside GHRH analogues.
The pulsatile nature of GH release stimulated by these peptides closely mimics the body’s natural secretion pattern. This is particularly important because GH exerts many of its effects through insulin-like growth factor 1 (IGF-1), which is produced in the liver in response to GH stimulation. A healthy, pulsatile GH pattern optimises IGF-1 production while maintaining metabolic balance.
GHRP-2 (10mg) is widely regarded as one of the most potent growth hormone releasing peptides available for research. This hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was among the first synthetic GHS compounds developed and has been extensively studied in both animal models and human clinical trials.
GHRP-2 acts as a potent agonist at the ghrelin receptor, stimulating GH release from the pituitary gland. What sets GHRP-2 apart from other GHS peptides is its particularly strong GH-releasing effect. Studies published in the Journal of Clinical Endocrinology & Metabolism have shown that GHRP-2 can increase GH levels by 7 to 15-fold above baseline, making it one of the most effective single-agent GH secretagogues available.
Beyond its primary action on the ghrelin receptor, GHRP-2 also influences appetite regulation, cortisol secretion, and prolactin levels. Research has demonstrated that GHRP-2 can stimulate mild increases in cortisol and prolactin, though these effects are generally transient and dose-dependent.
A landmark study published in Clinical Endocrinology demonstrated that GHRP-2 administration resulted in significant GH release in both young and elderly subjects, suggesting its utility in age-related GH decline research. The study found that while the absolute GH response was somewhat attenuated in older subjects, the relative increase remained clinically significant.
Australian researchers have shown particular interest in GHRP-2’s potential applications in sarcopenia research, wound healing studies, and metabolic investigations. The peptide’s well-characterised pharmacological profile makes it an ideal reference compound for comparative studies with newer GHS agents.
GHRP-6 (10mg) was one of the earliest growth hormone releasing peptides to be synthesised and remains a cornerstone of GHS research. This hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) shares structural similarities with GHRP-2 but exhibits distinct pharmacological properties that make it uniquely valuable for certain research applications.
Like GHRP-2, GHRP-6 acts primarily through the ghrelin receptor to stimulate GH release. However, GHRP-6 is notable for its stronger appetite-stimulating effects, which closely mirror those of endogenous ghrelin. This property has made GHRP-6 particularly valuable in research investigating the relationship between GH secretion and metabolic regulation.
Research published in Nature Reviews Endocrinology has highlighted that GHRP-6’s appetite-stimulating properties are mediated through both central and peripheral mechanisms, involving hypothalamic neuropeptide Y (NPY) and agouti-related peptide (AgRP) pathways.
GHRP-6 has been extensively studied for its cardioprotective properties. Research conducted at the Center for Genetic Engineering and Biotechnology in Havana demonstrated that GHRP-6 could reduce infarct size and improve cardiac function in animal models of myocardial ischaemia. These findings have sparked interest among Australian cardiovascular researchers exploring novel cardioprotective strategies.
Additionally, GHRP-6 has shown promise in wound healing research. Studies have demonstrated that the peptide can accelerate tissue repair through mechanisms involving increased collagen synthesis, angiogenesis, and anti-inflammatory effects. For Australian researchers studying chronic wound management — a significant healthcare challenge in remote and Indigenous communities — GHRP-6 represents a compelling area of investigation.
Ipamorelin (10mg) represents a significant advancement in growth hormone secretagogue design. This pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is distinguished by its remarkable selectivity for GH release, with minimal effects on cortisol, prolactin, and other hormones — a property that has made it one of the most popular GHS peptides for research worldwide.
Ipamorelin binds to the ghrelin receptor with high affinity but demonstrates a uniquely clean pharmacological profile. Unlike GHRP-2 and GHRP-6, which can stimulate cortisol and prolactin release at higher doses, Ipamorelin maintains its selectivity for GH release across a wide dose range. This selectivity has been attributed to its specific binding characteristics at the GHS-R1a receptor and its lack of significant interaction with other receptor systems.
A pivotal study published in the European Journal of Endocrinology confirmed that Ipamorelin stimulates GH release in a dose-dependent manner without affecting ACTH, cortisol, prolactin, FSH, LH, TSH, or GnRH levels. This clean profile makes Ipamorelin particularly valuable for research where confounding hormonal effects need to be minimised.
Ipamorelin has been studied extensively in the context of bone health research. Animal studies have demonstrated that Ipamorelin administration can increase bone mineral density and improve bone microarchitecture, findings that are particularly relevant given Australia’s ageing population and the growing burden of osteoporosis.
The peptide has also shown promise in gastrointestinal research. Studies have demonstrated that Ipamorelin can accelerate gastric emptying and improve intestinal motility, leading to investigations into its potential applications for post-operative ileus — a common complication following abdominal surgery.
Tesamorelin (10mg) stands apart from the other peptides in this guide because it works through a different mechanism. Rather than acting on the ghrelin receptor, Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates GH release through the GHRH receptor on pituitary somatotrophs.
Tesamorelin consists of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification enhances the peptide’s stability and bioavailability compared to native GHRH. By acting through the GHRH receptor pathway — which is complementary to the ghrelin receptor pathway used by GHRP-2, GHRP-6, and Ipamorelin — Tesamorelin offers researchers a tool to investigate GH regulation from a different angle.
Tesamorelin is notable for being one of the few GH-releasing peptides to have received regulatory approval for a specific clinical indication. The U.S. Food and Drug Administration approved Tesamorelin (marketed as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Clinical trials demonstrated that Tesamorelin reduced visceral adipose tissue by approximately 15-18% over 26 weeks of treatment.
Beyond lipodystrophy research, Tesamorelin has attracted attention for its potential cognitive benefits. A study published in the Annals of Neurology found that Tesamorelin improved cognitive function in older adults, particularly in areas of executive function and verbal memory. These findings have significant implications for Alzheimer’s disease and age-related cognitive decline research.
Choosing the right growth hormone peptide depends entirely on your research objectives. Here’s a practical comparison to help guide your decision:
For maximum GH release: GHRP-2 consistently produces the strongest GH response among the ghrelin receptor agonists, making it ideal for studies requiring robust GH stimulation.
For appetite and metabolic research: GHRP-6‘s pronounced appetite-stimulating effects make it the preferred choice for studies investigating the GH-appetite axis and metabolic regulation.
For clean, selective GH stimulation: Ipamorelin‘s minimal effects on cortisol and prolactin make it the gold standard for research requiring isolated GH stimulation without confounding hormonal changes.
For GHRH pathway research: Tesamorelin is the only GHRH analogue in this group, making it essential for studies investigating the GHRH receptor pathway or for combination protocols with ghrelin receptor agonists.
Australia has emerged as a significant hub for peptide research, with universities and research institutions across the country actively investigating growth hormone peptides. The National Health and Medical Research Council (NHMRC) has funded numerous studies exploring the therapeutic potential of GHS compounds, particularly in the areas of ageing, metabolic disease, and musculoskeletal health.
Australian researchers benefit from a regulatory environment that supports legitimate peptide research while maintaining appropriate safety standards. The TGA’s framework for research chemicals allows scientists to access high-quality peptides for in vitro and in vivo studies, contributing to Australia’s growing reputation in the global peptide research community.
The country’s unique demographic challenges — including a rapidly ageing population, high rates of obesity, and significant health disparities in rural and remote communities — provide compelling research questions that growth hormone peptides may help address. From investigating GH’s role in age-related sarcopenia to exploring metabolic interventions for obesity, Australian researchers are at the forefront of translating peptide science into practical health solutions.
The quality of research peptides directly impacts the reliability and reproducibility of experimental results. When sourcing growth hormone peptides in Australia, researchers should prioritise suppliers that provide third-party purity testing, typically via high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Purity levels of 98% or higher are generally considered acceptable for research applications.
At Aus Bio Peps, all growth hormone peptides undergo rigorous quality control testing to ensure they meet the highest standards for research use. Each batch is accompanied by a certificate of analysis (COA) documenting purity, identity, and peptide content — giving Australian researchers confidence in their experimental materials.
Growth hormone peptides represent just one facet of the broader peptide research landscape. Researchers interested in complementary areas may also want to explore healing and recovery peptides like BPC-157, which has shown synergistic effects with GH in tissue repair studies. Similarly, weight loss peptides such as AOD-9604 — a modified fragment of human growth hormone — offer insights into GH’s metabolic effects without full GH receptor activation.
For researchers investigating the cognitive effects of GH modulation, our cognitive peptides range provides complementary tools for studying neuroprotection and cognitive enhancement.
Growth hormone peptides represent a dynamic and rapidly evolving field of research with significant implications for human health. Whether you’re investigating the fundamental biology of GH secretion, exploring therapeutic applications for age-related conditions, or studying the complex interplay between growth hormone and metabolism, the peptides discussed in this guide — GHRP-2, GHRP-6, Ipamorelin, and Tesamorelin — provide a comprehensive toolkit for advancing our understanding of growth hormone biology.
Australia’s research community is uniquely positioned to make meaningful contributions to this field, and access to high-quality, rigorously tested peptides is fundamental to that mission. Browse our complete range of growth hormone peptides and take the next step in your research journey today.
Australia’s leading supplier of high-purity research peptides. Committed to scientific excellence and fast, secure domestic distribution.
Research Disclaimer: All products sold by Aus Bio Peps are strictly for laboratory research and development purposes only. These products are not for human consumption, medical, or diagnostic use. Please consult the TGA guidelines regarding research chemicals.
© 2026 Aus Bio Peps. All Rights Reserved. Based in Australia.
